Total Payments
$1.3M
2024 Payments
$115,772
Companies
42
Transactions
520
Medicare Patients
6,854
Medicare Billing
$1.1M
Payment Breakdown by Category
Royalty/License$1.3M (99.1%)
Food & Beverage$7,949 (0.6%)
Consulting$2,600 (0.2%)
Other$661.88 (0.1%)
Travel$102.60 (0.0%)
Education$16.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $1.3M | 32 | 99.1% |
| Food and Beverage | $7,949 | 484 | 0.6% |
| Consulting Fee | $2,600 | 1 | 0.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $661.88 | 1 | 0.1% |
| Travel and Lodging | $102.60 | 1 | 0.0% |
| Education | $16.50 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Wilson Cook Medical Incorporated | $1.3M | 34 | $0 (2024) |
| ABBVIE INC. | $2,413 | 148 | $0 (2024) |
| FUJIFILM Medical Systems USA, Inc. | $661.88 | 1 | $0 (2018) |
| PFIZER INC. | $652.38 | 41 | $0 (2024) |
| Janssen Biotech, Inc. | $575.29 | 34 | $0 (2024) |
| VIVUS LLC | $553.21 | 37 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $499.08 | 30 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $473.47 | 29 | $0 (2024) |
| Celgene Corporation | $427.50 | 33 | $0 (2024) |
| Ironwood Pharmaceuticals, Inc | $362.71 | 24 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $115,772 | 84 | Wilson Cook Medical Incorporated ($114,224) |
| 2023 | $144,445 | 87 | Wilson Cook Medical Incorporated ($143,041) |
| 2022 | $145,632 | 89 | Wilson Cook Medical Incorporated ($144,234) |
| 2021 | $176,167 | 82 | Wilson Cook Medical Incorporated ($174,935) |
| 2020 | $155,976 | 41 | Wilson Cook Medical Incorporated ($155,349) |
| 2019 | $166,541 | 62 | Wilson Cook Medical Incorporated ($165,685) |
| 2018 | $171,465 | 44 | Wilson Cook Medical Incorporated ($170,235) |
| 2017 | $214,321 | 31 | Wilson Cook Medical Incorporated ($213,990) |
All Payment Transactions
520 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $22.17 | General |
| Category: Gastroenterology | ||||||
| 12/10/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $15.75 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $32.08 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/03/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/25/2024 | VIVUS LLC | PANCREAZE (Drug) | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $21.68 | General |
| Category: Gastroenterology | ||||||
| 11/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $20.71 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/14/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/13/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/12/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $8.63 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $30.92 | General |
| Category: Immunology | ||||||
| 11/06/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/05/2024 | Wilson Cook Medical Incorporated | FUSION (Device) | Royalty or License | Cash or cash equivalent | $20,191.81 | General |
| Category: Endoscopy | ||||||
| 11/01/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $12.85 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/31/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.25 | General |
| Category: Immunology | ||||||
| 10/15/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $11.47 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/07/2024 | VIVUS LLC | PANCREAZE (Drug) | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/06/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $11.80 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/26/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: Immunology | ||||||
| 09/11/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ, HUMIRA | Food and Beverage | In-kind items and services | $34.53 | General |
| Category: IMMUNOLOGY | ||||||
| 09/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.16 | General |
| Category: Gastroenterology | ||||||
| 09/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $19.42 | General |
| Category: INTERNAL MEDICINE | ||||||
| 08/29/2024 | Fresenius Kabi USA, LLC | IDACIO (Biological) | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: Biosimilars | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 1,861 | 5,477 | $1.2M | $334,620 |
| 2022 | 28 | 1,853 | 4,693 | $1.1M | $315,392 |
| 2021 | 25 | 1,687 | 2,414 | $860,626 | $216,051 |
| 2020 | 20 | 1,453 | 1,730 | $826,503 | $193,618 |
Total Patients
6,854
Total Services
14,314
Medicare Billing
$1.1M
Procedure Codes
97
All Medicare Procedures & Services
97 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 188 | 2,147 | $214,700 | $76,548 | 35.7% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 188 | 1,256 | $150,720 | $58,470 | 38.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 262 | 373 | $70,870 | $33,449 | 47.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 137 | 139 | $113,285 | $28,326 | 25.0% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 97 | 98 | $76,440 | $16,445 | 21.5% |
| 43274 | Insertion of stent into pancreatic or bile duct using a flexible endoscope | Facility | 2023 | 39 | 44 | $57,640 | $14,791 | 25.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 115 | 115 | $33,350 | $13,585 | 40.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 167 | 194 | $24,250 | $12,132 | 50.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 135 | 145 | $66,120 | $9,394 | 14.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 77 | 77 | $62,370 | $9,166 | 14.7% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 43 | 235 | $35,250 | $8,631 | 24.5% |
| 43275 | Removal of stent from pancreatic or bile duct using a flexible endoscope | Facility | 2023 | 27 | 29 | $31,320 | $7,530 | 24.0% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 42 | 202 | $40,400 | $7,416 | 18.4% |
| 43276 | Replacement of stent in pancreatic or bile duct using a flexible endoscope | Facility | 2023 | 17 | 21 | $28,623 | $7,045 | 24.6% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 47 | 56 | $33,320 | $6,235 | 18.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 66 | 66 | $12,210 | $4,408 | 36.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 33 | 62 | $7,130 | $3,815 | 53.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 37 | 38 | $11,096 | $3,760 | 33.9% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 24 | 25 | $19,500 | $3,153 | 16.2% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 17 | 17 | $13,260 | $3,000 | 22.6% |
| 43264 | Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | Facility | 2023 | 36 | 46 | $62,238 | $2,200 | 3.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 31 | 55 | $5,610 | $2,081 | 37.1% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 22 | 22 | $9,900 | $1,730 | 17.5% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2023 | 14 | 15 | $6,900 | $1,309 | 19.0% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 152 | 1,788 | $178,800 | $65,279 | 36.5% |
About Dr. Stephen Deal, M.D
Dr. Stephen Deal, M.D is a Gastroenterology healthcare provider based in Charlotte, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1598783961.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Deal, M.D has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $115,772 received in 2024. These payments were reported across 520 transactions from 42 companies. The most common payment nature is "Royalty or License" ($1.3M).
As a Medicare-enrolled provider, Deal has provided services to 6,854 Medicare beneficiaries, totaling 14,314 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 97 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Charlotte, NC
- Active Since 07/17/2006
- Last Updated 05/04/2017
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1598783961
Products in Payments
- Cook Medical Biliary (Device) $532,322
- FUSION (Device) $257,265
- Fusion Quattro (Device) $174,950
- COOK MEDICAL BILIARY (Device) $170,235
- FUSION QUATTRO (Device) $144,290
- Cook Medical Endoscopy (Device) $2,703
- ESD - Core Endoscopy (Device) $661.88
- XELJANZ (Drug) $652.38
- HUMIRA (Biological) $651.23
- STELARA (Biological) $531.39
- Humira (Biological) $463.51
- XIFAXAN (Drug) $451.26
- ZEPOSIA (Drug) $432.09
- SKYRIZI (Biological) $379.46
- Linzess (Drug) $362.71
- RINVOQ (Biological) $339.76
- QSYMIA (Drug) $308.96
- Sucraid (Drug) $281.99
- ENTYVIO (Biological) $276.35
- CREON (Drug) $187.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Charlotte
Fred Fowler, M.d, M.D
Gastroenterology — Payments: $873,591
Gastroenterology $873,591
Nilesh Lodhia, Md, MD
Gastroenterology — Payments: $807,140
Gastroenterology $807,140
Oscar Brann, M.d, M.D
Gastroenterology — Payments: $246,482
Gastroenterology $246,482
Maithili Chitnavis, Md, MD
Gastroenterology — Payments: $179,660
Gastroenterology $179,660
Dr. Kent Holtzmuller, Md, MD
Gastroenterology — Payments: $160,162
Gastroenterology $160,162
Ronnie Cyzner, M.d, M.D
Gastroenterology — Payments: $78,895
Gastroenterology $78,895